AI Article Synopsis
- BNT162b2, the Pfizer/BioNTech COVID-19 vaccine, uses modified mRNA to produce the spike protein of the SARS-CoV-2 virus.
- There has been a rise in reported ocular complications and other immunological side effects associated with mRNA vaccines, indicating potential risks that are not yet completely understood.
- This report discusses a new case of sarcoidosis, characterized by uveitis and lung granuloma formation, which occurred shortly after receiving the first BNT162b2 vaccine dose, and reviews similar cases documented in existing literature.
Article Abstract
BNT162b2 (Pfizer/BioNTech) is a coronavirus disease 2019 (COVID-19) vaccine containing nucleoside-modified messenger RNA encoding the severe acute respiratory syndrome coronavirus 2 spike glycoprotein. Recently, ocular complications of mRNA vaccines have been reported increasingly frequently. However, immunological adverse events due to mRNA vaccines in real-world settings are not fully known. We herein report the novel development of sarcoidosis manifested as uveitis, bilateral hilar lymphadenopathy, angiotensin-converting enzyme elevation, and epithelioid and giant cell granuloma formation in the lung soon after the first BNT162b2 injection and review the current literature, including three reported cases of sarcoid-like reaction following COVID-19 vaccination.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9646347 | PMC |
| http://dx.doi.org/10.2169/internalmedicine.0104-22 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!